Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Is the 21st Century Cures bill in doubt over drug prices?
The Pharmalot View By Ed Silverman Why we shouldn’t trade a weakened FDA for more medical research funds
Exclusive By David Nather and Sheila Kaplan Public wary of faster approvals of new drugs, STAT-Harvard poll finds
Politics By Sheila Kaplan With comprehensive legislation stalled, Senate panel clears 7 smaller biomed bills